+1 (713) 400-6400
3200 Southwest Fwy #2240 Phoenix TowerHouston, TX 77027
© 2020 Marker Therapeutics, Inc.
“We remain grateful to the U.S. Department of Defense and Mayo Clinic for enabling TapImmune to gain invaluable clinical safety and efficacy insight for TPIV200 under this grant,” said TapImmune President and CEO Peter Hoang.
Get Marker News Delivered To Your Inbox